- Policy
- There are 17 cases of COVID-19 tx with stem cells worldwide
- by 박상준 May 21, 2020 06:01am
- As world-renowned pharmaceutical bio companies such as Gilead Sciences Korea, Novartis, and Pfizer have announced the development of COVID-19 treatment and vaccines, domestic pharmaceutical companies are also revealing their intentions through various mechanisms and strategies. In particular, it has attracted attention by offering various pos
- Product
- Hospitals ready to prescribe another CDK inhibitor Kisqali
- by Eo, Yun-Ho May 21, 2020 06:01am
- Following after Ibrance and Verzenio, a third cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor is landing its prescription code in Korean general hospitals. Pharmaceutical industry sources reported drug committees at eight major general hospitals like Seoul National University Hospital, Seoul Asan Medical Center, National Cancer Center
- Company
- Promising shingles vaccine market halved by COVID-19
- by Chon, Seung-Hyun May 21, 2020 06:01am
- The Korean shingles prevention vaccine market has halved this year. SK Bioscience' Sky Zoster has been maintaining high growth since its launch in 2018, but the market itself plummeted recently due to the COVID-19 outbreak. According to pharmaceutical market research firm IQVIA, this year’s first quarter shingles vaccine market marked
- Policy
- Lilly’s Baricitinib begins clinical trial of COVID-19
- by Lee, Tak-Sun May 21, 2020 06:00am
- Global pharmaceutical company Eli Lilly's rheumatoid arthritis treatment, 'Baricitinib' (Olumiant) is conducting sponsor-investigator trials on COVID-19 patients. So far, 10 drugs have been approved for clinical trials in COVID-19 patients, including Baricitinib. The MFDS approved a sponsor-investigator trials investigating COVID-19 for
- Company
- Anti-smoking treatment at public health centers was stopped
- by 박상준 May 20, 2020 06:12am
- From this year, the provision of smoking cessation treatments, such as Champix, through smoking cessation clinics in public health centers will disappear. The MOHW recently removed the provision of anti-smoking treatment Bupropion and Varenicline services from smoking cessation clinics in public health centers by revising the guidelines for t
- Company
- Yuhan, sell anticancer drug 'Glivec' with Novartis
- by Chon, Seung-Hyun May 20, 2020 06:11am
- Yuhan jointly sells anti-cancer drug 'Glivec' with Novartis. While Glivec's patent expired seven years ago, its growth slowed, but it intends to secure stable sales and overcome its recent sluggish earnings. On the 19th, Yuhan announced that it had signed a domestic exclusive sales and joint promotion agreement for Glivec with Novartis. Glive
- Opinion
- [Reporter’s View]Raising the voice of rare disease patients
- by Eo, Yun-Ho May 20, 2020 06:11am
- Seems like rare diseases put patients in utmost pain, because of its ‘rarity.’ Rare disease treatments can hardly prove cost-effectiveness and predictability with limited patient size for the reimbursement listing approval. Regardless, the Korean government is aware of the struggle. The revised drug pricing system the Ministry of Healt
- Company
- Daewon launches bone forming biosimilar Terrosa
- by Nho, Byung Chul May 20, 2020 06:11am
- On May 18, Daewon Pharmaceutical (CEO Baek Seung Ryel) announced the launch of a biosimilar treating patients with osteoporosis, Terrosa cartridge injection,. Richter-Helm BioTec, a joint venture between a German-based company Helm and a Hungarian-based company Gedeon Richter, has developed biosimilar Terrosa with an active ingredient te
- Policy
- Consult with PM from the development to post-marketing stage
- by Lee, Tak-Sun May 20, 2020 06:11am
- The MFDS (Minister Eui-kyung Lee) expanded the role of the 'product manager (PM)', which has been limited to the permitting step, from the drug development to the post-marketing cycle, in order to increase the predictability of the approval and review process and safety management expertise. Announced on the 18th that it will switch to a one-sto
- Company
- Samsung Bioepis' SB11 has equivalence with Lucentis
- by Lee, Seok-Jun May 20, 2020 06:10am
- SB11 (Ranibizumab), Lucentis' Biosimilar by Samsung Bioepis has demonstrated equivalence with the original. This is a global phase III for 705 people. SB11 is Samsung Bioepis' first ophthalmic disease treatment. It is also the sixth antibody biosimilar following three autoimmune disease treatments (SB2, SB4, and SB5) and two tumor disease tre
